DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Ojea A, Nogueira JL, Solsona E. et al.
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Eur Urol 2007;
52: 1398-1406
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.